Addex Therapeutics (ADXN) Competitors $8.00 -0.09 (-1.16%) Closing price 09/3/2025 03:50 PM EasternExtended Trading$8.22 +0.22 (+2.80%) As of 07:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. RNXT, DYAI, CLSD, ITRM, MAAQ, THAR, KZR, CASI, ALLR, and PMNShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include RenovoRx (RNXT), Dyadic International (DYAI), Clearside Biomedical (CLSD), Iterum Therapeutics (ITRM), Mana Capital Acquisition (MAAQ), Tharimmune (THAR), Kezar Life Sciences (KZR), CASI Pharmaceuticals (CASI), Allarity Therapeutics (ALLR), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors RenovoRx Dyadic International Clearside Biomedical Iterum Therapeutics Mana Capital Acquisition Tharimmune Kezar Life Sciences CASI Pharmaceuticals Allarity Therapeutics Promis Neurosciences RenovoRx (NASDAQ:RNXT) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation. Does the media favor RNXT or ADXN? In the previous week, RenovoRx and RenovoRx both had 1 articles in the media. RenovoRx's average media sentiment score of 0.00 equaled Addex Therapeutics'average media sentiment score. Company Overall Sentiment RenovoRx Neutral Addex Therapeutics Neutral Which has better earnings & valuation, RNXT or ADXN? Addex Therapeutics has higher revenue and earnings than RenovoRx. Addex Therapeutics is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovoRx$40K1,145.31-$8.81M-$0.38-3.29Addex Therapeutics$170.62K49.68$8.02M-$0.34-23.52 Is RNXT or ADXN more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to RenovoRx's net margin of 0.00%. Addex Therapeutics' return on equity of -54.27% beat RenovoRx's return on equity.Company Net Margins Return on Equity Return on Assets RenovoRxN/A -120.68% -89.23% Addex Therapeutics 3,584.49%-54.27%-49.15% Which has more volatility and risk, RNXT or ADXN? RenovoRx has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Do analysts prefer RNXT or ADXN? RenovoRx currently has a consensus price target of $7.50, indicating a potential upside of 500.00%. Addex Therapeutics has a consensus price target of $30.00, indicating a potential upside of 275.19%. Given RenovoRx's higher possible upside, research analysts clearly believe RenovoRx is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in RNXT or ADXN? 3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 9.1% of RenovoRx shares are owned by insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryAddex Therapeutics beats RenovoRx on 9 of the 13 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.57M$2.50B$5.77B$9.72BDividend YieldN/A48.51%6.66%4.49%P/E Ratio-23.5222.6482.6126.60Price / Sales49.68543.46504.06158.88Price / CashN/A26.3325.7028.92Price / Book0.776.7910.876.56Net Income$8.02M$32.94M$3.28B$266.04M7 Day Performance-0.61%0.80%0.10%-0.89%1 Month Performance-2.90%6.13%8.93%4.34%1 Year Performance-25.27%-0.23%51.11%24.06% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics1.8337 of 5 stars$8.00-1.2%$30.00+275.2%-30.6%$8.57M$170.62K-23.5230Gap UpRNXTRenovoRx2.052 of 5 stars$0.92+2.4%$7.25+688.0%+22.5%$33.72M$40K-2.426Short Interest ↑Gap UpDYAIDyadic International3.3616 of 5 stars$0.90+3.2%$6.00+568.2%-25.3%$32.50M$3.49M-4.737Positive NewsShort Interest ↓CLSDClearside Biomedical2.3516 of 5 stars$0.41+0.5%$4.20+937.0%-66.0%$31.80M$1.66M-1.0930ITRMIterum Therapeutics3.0956 of 5 stars$0.70-3.3%$9.00+1,191.2%-44.3%$31.13MN/A-0.8210Positive NewsShort Interest ↓MAAQMana Capital AcquisitionN/A$3.68+1.1%N/A+937.3%$29.90MN/A0.001Gap UpTHARTharimmune2.7602 of 5 stars$6.37-17.4%$17.00+167.0%+67.4%$29.63MN/A-1.052Short Interest ↑High Trading VolumeKZRKezar Life Sciences3.4721 of 5 stars$4.03+0.8%$9.00+123.3%-32.9%$29.50M$7M-0.4260CASICASI Pharmaceuticals3.6675 of 5 stars$2.34-3.7%$4.00+70.9%-64.2%$28.78M$28.54M-0.92180Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionGap DownALLRAllarity Therapeutics2.8214 of 5 stars$1.97+109.3%$9.00+356.9%-63.8%$28.73MN/A0.0010High Trading VolumePMNPromis Neurosciences2.4423 of 5 stars$0.55+2.7%$4.33+689.3%-64.9%$28.44MN/A-2.615News CoverageGap Down Related Companies and Tools Related Companies RenovoRx Alternatives Dyadic International Alternatives Clearside Biomedical Alternatives Iterum Therapeutics Alternatives Mana Capital Acquisition Alternatives Tharimmune Alternatives Kezar Life Sciences Alternatives CASI Pharmaceuticals Alternatives Allarity Therapeutics Alternatives Promis Neurosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
